Cetera Investment Advisers Acquires 7,852 Shares of DexCom, Inc. $DXCM

Cetera Investment Advisers raised its holdings in DexCom, Inc. (NASDAQ:DXCM) by 6.5% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 128,775 shares of the medical device company’s stock after acquiring an additional 7,852 shares during the period. Cetera Investment Advisers’ holdings in DexCom were worth $8,087,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Reflection Asset Management bought a new position in DexCom in the fourth quarter valued at $25,000. Ascentis Independent Advisors purchased a new position in shares of DexCom in the 1st quarter worth about $25,000. MCF Advisors LLC bought a new position in shares of DexCom during the 4th quarter valued at about $32,000. DV Equities LLC purchased a new position in shares of DexCom during the 4th quarter valued at about $36,000. Finally, Spire Wealth Management raised its holdings in shares of DexCom by 113.8% during the 4th quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock valued at $38,000 after buying an additional 305 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

More DexCom News

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly beat and higher outlook: DexCom reported adjusted earnings of $0.70 per share versus the $0.61 consensus, while revenue rose 13.1% year over year to $1.31 billion, exceeding estimates of $1.29 billion. Management raised its 2026 revenue outlook to approximately $5.18 billion-$5.25 billion, supported by strong global demand and broader product access. Reuters article
• Positive Sentiment: Product and market expansion: Growth is being supported by the G7 15 Day continuous glucose monitor, with DexCom targeting nearly 50% U.S. conversion by year-end, as well as expanded access and continued international growth. Margin improvement also contributed to a more constructive 2026 earnings narrative. Seeking Alpha article
• Positive Sentiment: Broad analyst support: Mizuho raised its price target to $95, Royal Bank of Canada and Wells Fargo lifted targets to $90, and UBS reaffirmed a Buy rating with a $96 target. Benchmark also reaffirmed Buy, although its $82 target is below the referenced trading level. Benzinga analyst updates
• Neutral Sentiment: Mixed valuation signals: JPMorgan raised its target substantially to $82 but retained a Neutral rating, indicating that some analysts view much of the improved outlook as already reflected in the stock.
• Negative Sentiment: Insider selling: Quiver Quantitative data shows 14 insider sales and no purchases during the past six months. This is a potential cautionary signal, although it has not outweighed the earnings-driven optimism. Quiver Quantitative analysis

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Wells Fargo & Company upped their target price on DexCom from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday. Mizuho lifted their price target on shares of DexCom from $90.00 to $95.00 and gave the stock an “outperform” rating in a research note on Friday. BTIG Research reissued a “buy” rating and set a $90.00 price target (up from $80.00) on shares of DexCom in a research note on Friday. Raymond James Financial restated a “strong-buy” rating and issued a $94.00 price objective on shares of DexCom in a report on Friday. Finally, TD Cowen reaffirmed a “buy” rating on shares of DexCom in a research note on Friday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average target price of $88.12.

DexCom Trading Up 12.0%

Shares of DXCM stock opened at $83.45 on Friday. The business has a 50-day moving average of $73.14 and a 200 day moving average of $69.20. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $87.00. The stock has a market capitalization of $32.20 billion, a PE ratio of 32.98, a P/E/G ratio of 1.23 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. DexCom had a return on equity of 35.34% and a net margin of 20.12%.The business had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. During the same period in the previous year, the firm earned $0.48 EPS. The business’s quarterly revenue was up 13.1% on a year-over-year basis. As a group, sell-side analysts anticipate that DexCom, Inc. will post 2.57 earnings per share for the current year.

Insider Transactions at DexCom

In related news, EVP Jon Coleman sold 4,912 shares of DexCom stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $73.00, for a total value of $358,576.00. Following the transaction, the executive vice president directly owned 100,361 shares of the company’s stock, valued at $7,326,353. The trade was a 4.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.55, for a total transaction of $128,435.00. Following the sale, the executive vice president directly owned 106,353 shares of the company’s stock, valued at $8,034,969.15. The trade was a 1.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 98,506 shares of company stock valued at $7,205,258. 0.28% of the stock is currently owned by insiders.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.